<DOC>
	<DOCNO>NCT02179970</DOCNO>
	<brief_summary>Pancreatic , ovarian colorectal cancer difficult treat use chemotherapy immune therapies.Currently patient offer treatment standard chemotherapy drug depend cancer type . Recently , laboratory study show drug call plerixafor may help body overcome resistance immune therapy . The purpose study find study drug effect patient advance pancreatic , ovarian colorectal cancer , see laboratory experiment , find right dose study drug give . This 'dose escalation study ' . Patients recruit slowly study team closely monitor effect drug , find best dose give . As part study , blood tumour sample collect analysed laboratory patient cancer monitor use two image technique , CT FDG-PET scan .</brief_summary>
	<brief_title>To Assess Safety Continuous IV Administration Plerixafor Patients With Advanced Pancreatic , Ovarian Colorectal Cancers</brief_title>
	<detailed_description>This prospective , non-randomised , open label , Phase I , dose escalation study plerixafor ( MozobilTM ) patient histological documentation advance pancreatic , high grade serous ovarian colorectal adenocarcinoma . We investigate feasibility administer plerixafor term safety , try identify proof mechanism patient . This study require establish whether relevant plasma concentration plerixafor achieve safely patient advance pancreatic , high grade serous ovarian colorectal cancer . Plerixafor ( Mozobil ) administer continuous 7 day intravenous infusion , start dose 20 ug/kg/hr , subsequent dose level 40 , 80 120 ug/kg/hr ( inpatient least initial 48 hour ) . 3 patient enter sequentially ( least 1 week apart ) , use standard 3+3 , Phase I trial design . Up 28 patient recruit .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Aged 16 year time signing informed consent form . Dose escalation phase : Patients inoperable , histologically prove locally advanced metastatic pancreatic , high grade serous ovarian colorectal adenocarcinoma , refractory conventional chemotherapy patient decline conventional chemotherapy . OR ; Expansion phase : Patients inoperable , histologically prove locally advanced metastatic pancreatic , refractory conventional chemotherapy patient decline conventional chemotherapy . Tumour lesion consider accessible core biopsy immunostaining assessment . ECOG performance status 01 . Life expectancy least 12 week . All woman childbearing potential sexually active male patient must agree use effective contraception method throughout study 3 month final dose study drug . Inadequate haematological function define : Absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L Absolute lymphocyte count &lt; normal level institution Haemoglobin &lt; 9.0 g/dL ( 90 g/L ) ( may increase level transfusion long evidence active bleeding ) Platelets &lt; 100 x 109/L Clotting ; INR &gt; 1.3 Inadequate renal function define calculated creatinine clearance CockcroftGault &lt; 50 ml/min . Inadequate hepatic function define : Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) &gt; 5 x presence liver metastases Total bilirubin &gt; 1.5 x ULN Current treatment ( within 28 day entry ) chemotherapy , steroid immunosuppressive drug . Significant acute chronic medical psychiatric condition , disease laboratory abnormality judgment Investigator would place patient undue risk interfere study . Cardiac comorbidity : Past history significant rhythm disturbance ( e.g . SVT , AF ventricular irregularity ) Requirement pacemaker . Myocardial infarction previous 6 month . Known medical history proven postural hypotension . Active infection . Patients know allergy plerixafor excipients . Patients know hepatitis B , hepatitis C HIV infection . Women , pregnant , plan become pregnant lactating ( study 3 month last dose )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced pancreatic cancer</keyword>
	<keyword>Advanced ovarian cancer</keyword>
	<keyword>Advanced colorectal cancer</keyword>
	<keyword>Metastatic pancreatic cancer</keyword>
	<keyword>Metastatic ovarian cancer</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
</DOC>